Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Sign in Sign up
MANE

Veradermics, Incorporated
MANE
Market cap $1.35B

Overview Fund Trends Analyst Outlook Journalist POV
38.48 USD
+1.32
3.55%
At close Updated Feb 6, 4:00 PM EST
Pre-market
After hours
36.18
-2.30
5.98%
1 day
3.55%
5 days
13.18%
1 month
1.93%
3 months
1.93%
6 months
1.93%
Year to date
1.93%
1 year
1.93%
5 years
1.93%
10 years
1.93%
Upgrade to unlock
Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 50%
Negative

Positive
Seeking Alpha
yesterday
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week.
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Neutral
Business Wire
2 days ago
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exerc.
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
See News Rankings
Product
Portfolios Fund Trends Large Buys & Sells Analyst Upside Analyst Price Targets Analysts Analyst Firms Stocks ETFs Sectors Industries Rankings
Resources
Plans Learn API Access
Policies
Terms & Conditions Privacy Policy Disclaimer Climate Commitment
Connect
Contact Us X (Twitter) LinkedIn

© 2026 Wall St. Rank

Sign up Sign in
Common Fund Bets See what stocks and ETFs funds are collectively bullish/bearish on Largest Fund Trades Explore the largest stock and ETF buys and sells made by funds High Conviction Trades Discover high conviction trades that caused a significant change in a fund's stake in a stock Fund Manager Portfolios Gain insights from the world’s largest funds and super investors
Price Target Consensus See what stocks research analysts are collectively bullish/bearish on Latest Ratings Feed Explore the latest ratings and price targets from the best equity research analysts Equity Analyst Profiles Browse analysts, their latest ratings and track record Research Firm Profiles Browse research firm recommendations, trends, and performance
Fund Manager Index Stock index based on fund manager consensus updated each quarter Analyst Index COMING SOON - Stock index based on equity analyst consensus updated every second

Theme